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Mind the gaps: therapists’ experiences of managing
symptomatic hypermobility in Scotland
Dervil M. Dockrell *, Kathryn M. Berg,* and Stuart H. Ralston
Abstract
Objectives The aim was to ascertain occupational therapist (OT) and physiotherapist (PT) experien-
ces of managing hypermobility spectrum disorders (HSDs) and hypermobile Ehlers-Danlos syndrome
(hEDS) patients, specifically the training and confidence levels of therapists, use of evidence-based
practice, accessibility of pain management and clinical psychology services, and perceived usefulness
of a specialist centre in Scotland.
Methods A mixed-method survey was distributed to Rheumatology OTs/PTs in Scotland. It included
multiple choice and open text questions, which were analysed to reflect therapists’ experiences and
perception of service need.
Results We found that therapists in Scotland do have expertise in the management of HSD/hEDS
patients; however, this expertise tends to be concentrated in secondary care, which makes it difficult
for patients who are managed in primary care to access. The majority of respondents reported lack of
access to external training (80%). There was difficulty in referral to pain management services (55%)
and clinical psychology (28%) among adult therapists. Paediatric services provided considerably better
access to these disciplines. Of note, the majority of respondents were in favour of a specialist centre
in Scotland for the training and education of therapists (94.7%) and the diagnosis and management of
complex HSD/hEDS patients (73.7%).
Conclusion More research is needed urgently to evaluate the effectiveness of therapy interventions
to underpin a national guideline in order that we can improve outcomes for HSD/hEDS patients. A spe-
cialist centre with expert and engaged clinicians would be a valuable asset in coordinating patient-
focused research and conducting good-quality clinical trials.
Key words: occupational therapist, physiotherapist, hypermobile spectrum disorder, hypermobile Ehlers-
Danlos syndrome, Scotland
Introduction
Joint hypermobility is defined as the ability to move
joints beyond the normal range of movement [1]. For
some individuals it can cause symptoms of pain, swell-
ing, stiffness and subluxation, which can adversely af-
fect quality of life [2]. The Ehlers-Danlos syndromes
(EDS) are a group of heritable connective tissue
Key messages
. Despite therapy expertise, there is still unmet need and discrepancy in service provision for hypermobility
spectrum disorder/hypermobile Ehlers-Danlos syndrome patients in Scotland.
. A specialist centre for this patient group in Scotland would be valuable.
. More research is required to underpin national therapy guidelines for treatment of adult hypermobility spectrum
disorder/hypermobile Ehlers-Danlos syndrome patients.
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disorders caused by mutations in genes that encode
collagen and other molecules involved in maintenance of
soft tissues [3]. The 2017 International Classification of
EDS refined the criteria for the 13 types of EDS, of which
hypermobile EDS (hEDS) is a subtype. Unlike the other
forms, hEDS is thought to be polygenic in nature and
cannot be diagnosed by molecular genetic testing. It is
characterized by joint hypermobility, skin flexibility and
tissue fragility [4]. Where criteria are not met for hEDS or
any other connective tissue disorder, a diagnosis of
hypermobility spectrum disorder (HSD) may be given.
HSD and hEDS can significantly impair health and
wellbeing and present a challenge for health professionals
to manage [5–8]. Recent work suggests that these diagno-
ses can affect many systems [9], not only the musculo-
skeletal system [10–15]. The presence of non-
musculoskeletal symptoms is not included in the diagnos-
tic criteria of hEDS, but these conditions can be more lim-
iting than the musculoskeletal symptoms themselves [16].
It has been acknowledged that the availability and
quality of services for patients with HSD/hEDS in the
National Health Service (NHS) varies widely [17]. The time
from onset of symptoms to diagnosis and treatment can
be lengthy, which can have a negative impact on patient
outcomes [12]. In 2017, the Scottish Government com-
mitted to reviewing services for EDS patients in response
to patient feedback that indicated an apparent lack of co-
ordinated care and access to treatment [18].
EDS Support UK does not verify the diagnoses of
their members but has recorded 466 patients in
Scotland with hEDS and 60 with HSD (Julier, K., Ehlers-
Danlos Support UK, 2020 written communication, 1
December). It is thought that the true prevalence of
HSD/hEDS is unknown because it is widely underdiag-
nosed despite symptoms presenting commonly in rheu-
matology clinics [19]. In 2017, the charity conducted a
survey of its patient members in Scotland. The survey
recorded 19 years being the average length of time be-
tween symptom presentation and diagnosis in Scotland.
Eighty-seven per cent of respondents felt that their con-
dition was not well supported by the NHS. Eighty-three
per cent reported that they did not have access to a
medical professional knowledgeable about their condi-
tion [20].
A 2020 report on behalf of EDS Support UK discusses
the experience of young people with HSD/EDS in
Scotland. The report states that young patients in
Scotland perceive the attitudes of health-care professio-
nals to be negative. This is particularly prevalent in
young females, who report that their symptoms are not
believed. The diagnostic journey for EDS/HSD patients
is problematic, and the report revealed an inequity of
service access in Scotland, with most patients surveyed
reporting that they had to travel to London to receive a
diagnosis. The report advocates for better education
and training of health professionals in Scotland and the
need for better service access geographically [21].
Although there are several reports related to the pa-
tient experience of the management and diagnosis of
HSD/hEDS in Scotland, the viewpoints of therapists are
underrepresented in the literature. The primary aim of
this study was to capture the perceptions and experien-
ces of occupational therapists (OTs) and physiothera-
pists (PTs) who manage patients with HSD and hEDS in
Scotland. The secondary aim was to ascertain whether
there is a need for a specialist centre in Scotland.
Methods
A cross-sectional mixed-methods questionnaire was
designed (see Supplementary Data S1, available at
Rheumatology Advances in Practice online). A mixture of
Likert scales, checkboxes and descriptive questions
were used. It was determined that a purposeful sam-
pling method was most appropriate for this study.
The questionnaire was constructed to gather informa-
tion on the facilities and resources available to thera-
pists working with hypermobility, the extent to which
they were confident in assessing those patients, the
techniques and outcomes they used and the clinical
characteristics of their caseloads. The survey questions
reflected interventions recommended in the literature for
treating rheumatology patients [22–25].
The survey respondents were identified as members
of registered professional bodies currently managing
patients with symptomatic hypermobility in Scotland.
OTs and PTs who were known to be members of regis-
tered professional bodies such as the British Society for
Rheumatology (BSR), the Scottish Paediatric and
Adolescent Rheumatology Network, and the Royal
College of Occupational Therapists Rheumatology
Clinical Forum were invited to complete the survey, be-
cause these bodies were determined to be most likely
to represent allied health professionals treating these
patients.
A total of 20 responses representing 11 of the 14
Scottish health boards were received. Eighty per cent of
the respondents worked in hospitals, representing a
secondary care service. Fifty-five per cent of the
respondents treated adults and young people [16–25];
the other 45% treated paediatric patients 19 years of
age.
Data were coded in Excel. The following themes were
identified: referrals and appointments; clinical practice;
therapist proficiency; other service access; and service
needs. Statistical significance was determined using
Fisher’s exact test in Minitab 17 software to compare
categorical values. Ethical approval was not required for
this study as determined by the UK policy framework for
Health and Social Care Research.
Results
Referrals and appointments
The most common referral sources reported by
respondents were through rheumatology teams (95%).
Sixty per cent of therapists also reported referrals from
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general practitioners (GPs). Other referral sources
reported were orthopaedics (25%), cardiology (10%),
gastroenterology (5%), genetics (5%) and schools
(10%).
Most of the respondents (65%) reported that their
referrals did not use the 2017 terminology. Other termi-
nology used included the terms JHS, BJHS, EDS type III
and EDS hypermobility type.
Therapists were asked how many HSD/hEDS patients
they treated in a usual calendar month. Most (60%)
therapists saw fewer than five HSD/hEDS patients per
month. Twenty-five per cent of therapists had a case-
load of between 5 and 10 patients, and 15% saw >10
patients per month. Twenty-five per cent of therapists
reported that they see other types of EDS patients.
Two respondents used free text to highlight the lack
of specific hypermobility referrals in their caseloads:
“[Hypermobility] would only be as a secondary diag-
nosis to an inflammatory arthritis in most cases, we do
not take referrals purely for the diagnosis of hypermobil-
ity. We would take a referral for EDS and more compli-
cated cases but these are rare.” Respondent number 6.
“Hypermobility is often not the primary diagnosis on
the referral.” Respondent number 5.
Thirty-five per cent of respondents reported that more
than half of their caseload was represented by patients
with complex needs. The complex needs reported can
be found in the questionnaire in the Supplementary
Material, available at Rheumatology Advances in
Practice online.
All respondents reported that they were able to offer
more than one appointment for patients under their
care. Six therapists (30%) reported that >50% of their
patient caseload required four or more sessions.
Clinical practice
A copy of the questionnaire used and a list of the as-
sessment areas surveyed can be found in the supple-
mentary material (see Supplementary Table S1,
available at Rheumatology Advances in Practice online).
Common areas of assessment (represented by 85% of
all therapists) were: work and education (95%); exercise
and hobbies (95%); and fatigue (95%).
Any differences between OTs and PTs were deter-
mined to be discipline related; for example, OTs were
more likely to assess functional activities, such as per-
sonal activities of daily living, domestic activities of daily
living, handwriting and computer use, whereas PTs were
more likely to assess areas such as muscle length, mus-
cle strength, gait and balance.
Table 1 summarizes the types and popularity of treat-
ment interventions used by therapists when treating
HSD/hEDS patients. As with the assessments, differen-
ces between OT and PT treatment interventions were
determined to be discipline specific; hence, statistical
analysis was considered to be redundant.
One respondent indicated that a lengthy diagnosis
may act as a barrier to effective treatment of HSD/hEDS
patients in their caseload:
"My feeling is that referral onto me is often too late as
individuals have already well-established bad habits".
Respondent number 1.
Fifty-seven per cent of PTs and 62% of OTs reported
that they used outcome measures to assess the effec-
tiveness of treatment in patients (see Supplementary
Table S2, available at Rheumatology Advances in
Practice online, for a list of the types of outcome meas-
ures reported).
Therapist proficiency
When asked what training they had received to assess
and treat HSD and hEDS patients, six respondents
(30%) had received external training (see Supplementary
Table S3, available at Rheumatology Advances in
Practice online), four (20%) therapists had visited other
centres, five (25%) reported that they had received in-
house training, and 95% reported that they had under-
taken self-directed training. Of those who worked with
young people and paediatric patients, 50% reported
that they were aware of the British Society for Paediatric
TABLE 1 Treatment interventions used by therapists
Treatment intervention Occupational therapist (n 5 13) Physiotherapist (n 5 7) All therapists (n 5 20)
n Percentage n Percentage n Percentage
Energy conservation principles 13 100 7 100 20 100
Self-management 12 92 7 100 19 95
Joint protection techniques 12 92 3 43 15 75
Sleep hygiene 10 77 5 71 15 75
Home exercise programme 5 39 7 100 12 60
Hand therapy 8 62 2 29 10 50
Motivational interviewing 6 46 4 57 10 50
Relaxation skills 6 46 4 57 10 50
Cognitive behavioural approach 4 31 3 43 7 35
Other* 2 15 2 29 4 20
*Other includes hydrotherapy, mindfulness, yoga, tai chi and Pilates.
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and Adolescent Rheumatology (BSPAR, now integrated
into BSR) guidelines for the assessment and treatment
of symptomatic hypermobility.
There were no statistically significant differences be-
tween the confidence levels of OTs and PTs in dealing
with HSD/hEDS, despite the fact that 31% of OTs
reported that they were not confident in the manage-
ment of patients with HSD/hEDS. Overall, 80% of thera-
pists reported that they were confident in the
assessment and treatment of HSD/hEDS (Table 2).
Respondent-reported service access
Few therapists (55%) managing adults had access to a
pain management programme compared with 89% of
therapists managing paediatric patients, but the differ-
ence was not statistically significant when calculated us-
ing Fisher’s exact test (P¼0.157).
Fewer therapists managing adults reported access to
a clinical psychologist (28%) compared with 89% of
paediatric therapists, and this was highly significant
when calculated using Fisher’s exact test (P¼ 0.009;
see Fig. 1).
Need for a specialist centre
The majority of respondents were in favour of a special-
ist centre for the management and treatment of patients
and for the training and education of therapists (see
Figs 2 and 3). However, one therapist noted that if HSD/
hEDS patients were discharged back to a local centre
for the implementation of their treatment plan, they
would be unable to absorb the extra workload. This sug-
gests that there is a need for further investment in re-
cruitment and training of additional specialist therapists:
"I do not have the capacity to see increased patient
numbers, especially if there is an expectation on the
part of all patients with EDS going through such a cen-
tre." Respondent number 1.
Discussion
The purpose of this study was to collate the experiences
of Scottish rheumatology therapists in the management
of patients with HSD and hEDS and to ascertain
whether there is a need for a specialist centre. In the
absence of specific guidelines for OTs on management of
adult patients with HSD and hEDS, the literature recom-
mends OT as part of an MDT approach to managing
patients [1]. The biopsychosocial model of care, which is
the core approach for OTs, is advocated by Baeza-Velasco
et al. [26] for patients with hypermobility. Hammond [27]
reports self-management programmes, joint protection
education, fatigue and mood management, activity and
role planning, goal setting and counselling as OT inter-
ventions for chronic musculoskeletal conditions.
All OTs used the recommended treatments, but some
of these were used by as few as one-third of therapists.
PT respondents reported similar adherence to the evi-
dence base for treatment strategies, with the emphasis
on active vs passive treatment. More than half (57%) did
not report using specific joint protection techniques as
advocated in the literature [28, 29].
Current therapy management is largely the same for
HSD and hEDS, although there is a paucity of quality lit-
erature on the clinical and economic effectiveness of
interventions. Russek et al. [25] outlined the diagnosis
and management of patients with HSD and hEDS for
PTs. They explored the terminology of the diagnoses
and complexity of the condition. Evaluation and treat-
ment strategies for patients are recommended, with an
emphasis that therapists who are knowledgeable about
the conditions should provide such treatment. Owing to
the limited research on the best therapeutic interven-
tions, therapists should rely on their clinical experience
and patient partiality.
More than one-third of the therapists did not use
quantitative outcome measures to evaluate patient treat-
ment, and only one respondent indicated that they used
a specific hypermobility outcome measure for hypermo-
bility. This is reflective of the lack of evidence in the liter-
ature regarding effectiveness of interventions [25, 28].
Where outcome measures are used (see Supplementary
Material, available at Rheumatology Advances in
Practice online), they are consistent with those reported
in the survey by Palmer et al. [30] of PTs in 2015, indi-
cating that practice is evidence based. The majority of
the therapists reported that they were moderately confi-
dent in the assessment and treatment of patients with
HSD/hEDS, but only 20% had previously received any
specialist training. Nearly all (94.7%) respondents were
TABLE 2 Subjective confidence levels of therapists in the management of HSD/hEDS patients
Confidence level OT PT Overall P-value
n Percentage n Percentage n Percentage
Very confident 0 0 2 29 2 10 P¼0.110
Moderately confident 9 69 5 71 14 70 P¼1.000
Not confident 4 31 0 0 4 20 P¼0.248
Significance was determined as P<0.05. No significance was found when calculated using Fisher’s exact test.
OT: occupational therapist; PT: physiotherapist.
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in favour of a specialist centre for education and training
in the management of HSD/hEDS.
Few of the therapists who were dealing with adult
patients had access to a clinical psychologist. This is
important because anxiety and depression are highly
prevalent symptoms in this patient group, and it is likely
that they are not being addressed appropriately [24].
This is in contrast to the paediatric population, in which
nearly 90% of therapists reported access to this service.
It has been demonstrated that psychological distress is
significantly higher in patients with hypermobility than in
those without [31]. Although pain has a moderate impact
on disability, fatigue, anxiety and depression have more
of an impact on health in this patient group [32]. A study
by Bennett et al. [33] concluded that there was a need
to heighten awareness of hypermobility in the health-
care professional to improve outcomes for patients.
Clinical psychology is a valuable resource in the treat-
ment of HSD/hEDS. Patients have a higher likelihood of
anxiety, depression and panic disorders [34] and report
feelings of guilt and low self-esteem, often resulting
from a poor perception of the condition among the
health-care community [35]. Patients often report a
lengthy wait between the onset of symptoms and the di-
agnosis of HSD/hEDS and may see a number of
different health professionals. This can exacerbate feel-
ings of anxiety and depression. A 2016 study by
Scheper et al. [32] suggested that emotional health in
this patient group influenced their wellbeing more than
physical discomfort.
Only 55% of therapists treating adults reported ac-
cess to a pain management programme, compared with
89% of those managing paediatric patients. Pain man-
agement services provide settings in which patients are
offered a rehabilitative psychological approach to pain
self-management. The programme can be individual or
group based. Rahman et al. [36] developed a condition-
specific pain management programme for hypermobility
patients. The results of several outcome measures sug-
gested that improvement was substantial and continu-
ous. It is our view that such a service would be
fundamental in the management of HSD/hEDS patients.
Despite the clarifications made in the 2017 EDS
International Classification regarding the nomenclature
of HSD/hEDS, the majority of our respondents (65%)
reported that the referrals they received from services
used the older terminologies. The authors suggest that
this continued use of previous nosology could demon-
strate a lack of awareness of the current classification
criteria and recent literature among the various medical
FIG. 1 Respondent-reported access to pain management and clinical psychology services
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specialities who referred patients to therapy. However, it
should be noted that if hypermobility was not newly di-
agnosed at the time of referral, then historical terminol-
ogy might be used.
These results suggest that therapists do assess and
treat HSD and hEDS patients according to the available
evidence base. However, it is clear that more training
and education are required for therapists to assess and
treat patients consistently across Scotland. The majority
(94.7%) of therapists were in favour of a specialist cen-
tre to provide this service. This is bolstered by the 2020
EDS Support UK report, which revealed an inequity of
service access in Scotland [21].
The BSR issued a statement in March 2020 conclud-
ing that there was insufficient evidence for them to de-
velop a guideline for the management of hypermobility
at present [37, 38]. The Royal College of General
Practitioners (RCGP) toolkit was developed in conjunc-
tion with EDS UK in 2018 [39], but raised safeguarding
issues for children with the diagnosis [37, 40]. This tool-
kit was to be removed from the RCGP website but will
remain for the present (Ehlers-Danlos Support UK, 2021,
written communication updated 1 February 2021).
The Hypermobility Syndromes Association (HMSA)
Kent Model provides training resources for the health
professional [41]. The EDS Society runs Project ECHO,
with training courses for professionals and allied health
professionals [42, 43]. The Scottish Paediatric
Adolescent Rheumatology Network (SPARN) has a rec-
ommended pathway of care for children with joint
hypermobility [44]. In 2019, the allied health professional
members of BSPAR reviewed their guidelines for man-
agement of children and young adults with symptomatic
hypermobility [45]. These guidelines have been criticized
by members of EDS patient support groups in the USA
and the UK for a number of reasons, including the as-
sertion that difficulties occur mainly when the body is
weak, the guidance that gastrointestinal and urinary in-
volvement is rare, and the fact that patient groups were
not involved in the development of the recommenda-
tions [46].
Despite the availability of information on the manage-
ment of HSD/hEDS, the reality is that accessing appro-
priate health-care support is very difficult for patients in
Scotland [21]. The recommended pathway for patients
with symptomatic hypermobility is diagnosis by GP
FIG. 2 Percentage of therapists who answered ‘Yes’ to the question, ‘How useful would a specialist centre for the
management and treatment of patients be?’
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followed by self-care information, physiotherapy and ex-
ercise, occupational therapy, podiatry, pain killers and
pain management. Other systemic problems may also
be diagnosed by the GP or referred to a hospital speci-
ality [47].
In the absence of a specialist centre, National
Services Division Scotland (NSD) commissions a highly
specialist diagnostic service for complex EDS patients
through their block agreement with NHS England. The
NHS England-commissioned service comes into play for
very difficult cases. Although this service offers manage-
ment advice, there is no access to specialist PTs or
OTs. This diagnostic service is highly specialized, with
narrowly defined acceptance criteria, which most hEDS/
HSD patients in Scotland would not meet, limiting pa-
tient access to the service. Access is also limited by a
reluctance to refer by clinicians, who may not know that
the service exists or may not feel that the condition war-
rants specialist diagnosis.
A few cases are referred each year to specialist resi-
dential programmes offered by a number of trusts in
England. These programmes offer access to specialist
PTs and OTs with extensive experience in treating this
cohort. Given that these services are not commissioned
by NHS England, NSD does not normally fund referrals,
although funding has been authorized in the past for
some patients. The number of Scottish patients access-
ing these programmes may be considerably higher, be-
cause individual health boards may have opted to fund
referrals for some of their patients without notifying
NSD. In addition, patient organizations have highlighted
that many patients have accessed these programmes
through private insurance or chosen to self-fund (Roexe,
A., National Services Division Scotland, 2021, written
communication, 22 January).
It is clear from the results of the present study and
from recent work published by EDS UK that an equiva-
lent centre in Scotland would be welcomed by the ma-
jority of therapists and patients. The current pathways of
care present challenges for HSD/hEDS patients, and
there is a poor representation of relevant and necessary
professions managing this patient group. These patients
FIG. 3 Percentage of therapists who answered ‘Yes’ to the question, ‘How useful would a specialist centre for the
training and education of therapists be?’
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are substantial users of secondary care services in NHS
Scotland, and yet their needs remain unmet. It is our
opinion that an investment in the diagnosis and man-
agement of HSD/hEDS is long overdue in Scotland and
must be addressed imminently.
Conclusion
The study has some limitations. The sample size was
small and limited to musculoskeletal therapists working
with hypermobility patients in Scotland. Surveying a
larger sample of therapists would be of interest, particu-
larly those working outside rheumatology.
We conclude that there is OT and PT expertise in
management of HSD and hEDS patients in Scotland. A
specialist centre would be welcomed by a majority of
therapists. Important services, such as pain manage-
ment and clinical psychology, are difficult to access.
Current specialist PT and OT services are mainly
accessed through or concentrated in secondary care.
The authors recommend an investment in primary care
capacity for this patient group, particularly in the avail-
ability of specialist OT and PT services, which are poorly
represented in primary care. A combined OT/PT ap-
proach would provide more holistic patient manage-
ment. It is our opinion that clinicians in a specialist
centre would be well placed to provide training and edu-
cation to bolster the expertise of a primary care
workforce.
For complex cases, clinicians in a specialist centre
would also be able to develop a patient management
plan to be maintained in primary care. This would lessen
the burden on secondary care services and provide lo-
cal access for patients. The availability of pain manage-
ment and clinical psychology services is inequitable
between adult and paediatric services. All patients
should have access to these services, preferably in the
community but at the very least through secondary care
or a specialist centre.
More research is needed urgently to evaluate the ef-
fectiveness of interventions to underpin a national guide-
line in order that we can improve outcomes for these
patients. A specialist centre with expert and engaged
clinicians would be a valuable asset in coordinating pa-
tient-focused research and conducting good-quality clin-
ical trials.
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